Angelo terapija, MB

Company age: 2 y. 10 mo.

Update

Company overview

Company name Angelo terapija, MB
Company code 306627767
VAT code LT100017914715
Registered address Naujoji Akmenė, Ramučių g. 2-3, LT-85137
Registration date 2023-11-15 Company age: 2 y. 10 mo.
Phone Phone
Email Email
Revenue (2025) 41,334 € +327% History
Profit (2025) 3,586 € +42% History
Number of employees 0
Managed vehicles 1 List
Current SODRA debt No debt Read more
Days of debt to SODRA per year 0 days
Current VMI debt No debt Read more
Financial statements All submitted
Legal form Small partnership
NACE activity Retail sale of cosmetic and toilet articles
Ownership form Private without foreign capital

Download a detailed company report

Make confident decisions with all the information about Angelo terapija, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.

19.99 € + PVM Get report

Description

This description was generated by artificial intelligence.
Angelo terapija, MB (company code 306627767) is an operational private small partnership registered on 15 November 2023. The company is classified as a micro-sized private entity in the national private non-financial companies sector, under private ownership, with governance described as CEO only. It is based in Naujoji Akmene, Ramuciu g. 2-3, Akmenes district municipality, Šiauliai County. The company’s activity is classified under EVRK code G.47.75.00, retail sale of cosmetic and toilet articles. Financial results show rapid growth in recent years. Revenue increased from €721 in 2023, during a 46-day first reporting period, to €9.7K in 2024 and €41.3K in 2025. Net profit was €259 in 2023, €2.5K in 2024 and €3.6K in 2025. Profit margin was 35.9% in 2023, 26.1% in 2024 and 8.7% in 2025, indicating that profitability remained positive while narrowing as turnover expanded. At the end of 2025, equity stood at €6.4K and liabilities at €490, with total assets of €6.9K. The latest available financial year shows a strong increase in scale alongside a still conservatively financed balance sheet.